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ABSTRACT
Treatment of U20S cells with the chemotherapeutic drug Doxorubicin results in either
apoptosis or cellular senescence. The pathway the cell takes is dependent upon the
dosage of Doxorubicin administered to the cells. When a 10 giM dose is administered
Topoisomerase II is inhibited resulting in double stranded DNA breaks because the DNA
is unable to religate during synthesis. This is shown by lower levels of synthesis after
analysis with Bromo-2-deoxyuridine (BrdU) and Propidium Iodide (PI) staining. The
cells are unable to recover from the severity of this damage and become apoptotic. When
a 2 gIM dose is applied to the cells, a G2 arrest occurs. This is shown by lower levels of
Cyclin B in the G2 phase during flow cytometry analysis and staining with PI.
Apoptosis levels are monitored using cleaved Caspase 3 and cleaved PARP. The
percentage of 10 giM cells undergoing apoptosis increased steadily over 48 hours, while
the 2 giM and untreated cells maintained constant low levels of apoptosis. Both cellular
senescence and apoptosis put a halt to cell proliferation.
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Thesis Supervisor: Nicolas G. Hadjiconstantinou
Title: Associate Professor of Mechanical Engineering
Introduction
Cancer is one of the most common causes of death in the world. In the United
States cancer kills close to 1,500 Americans each day (Medical News Today). Cancerous
tumors arise from actively dividing cells. The high rates of proliferation for these cells
put them at a high risk for developing mutations - a main cause of cancer (Campisi,
2003). Cancer is commonly treated with chemotherapy (National Cancer Institute). A
commonly used chemotherapeutic agent is Doxorubicin. This particular drug acts by
inhibiting the DNA ligase activity of Topoisomerase II (Jarvinen). As such, during
replication, the topoisomerase II can cut the DNA double helix but not re-ligate. This
creates damage within the cell when the DNA cannot recoil resulting in double stranded
breaks. One outcome of DNA damage is apoptosis (programmed cell death). The other
outcome is cell cycle arrests. These arrests occur in the cell cycle to allow the DNA to
repair before DNA synthesis and mitosis (Dipaola). Our goal is to experimentally
determine where these arrests occur. Using flow cytometry we will measure the proteins
responsible for controlling the cell cycle and determine how their levels change after
treatment with Doxorubicin. This allows us to understand the relationship between the
dosage of Doxorubicin administered and the resulting cell cycle arrests and apoptosis.
The cell cycle is comprised of four different stages - G1, G2, S and M. During
these phases DNA is replicated and mitosis occurs, creating a new cell. Cyclins and
cyclin dependent kinases (cdks), control the progression through the cell cycle
(Senderowicz). Kinases transfer phosphate groups from ATP to protein substrates. This
post-translational modification alters the activity of the kinase substrate. Cyclin
dependent kinases are activated by cyclins and proceed by phosphorylating serine and
threonine residues. During Gi, the target of the cdks is the retinoblasta protein (pRb),
which monitors transcription (Schafer). The cdks work with four cyclins involved in the
cell cycle - cyclin D, cyclin E, cyclin A, and cyclin B. Cyclin D acts with cdk 4, E and A
with cdk 2 and B with cdkl. This can be seen in Figure 1 below.
Figure 1. Cell Cycle - The cell cycle is comprised of four stages: Gl, S, G2 and M (mitosis). The cyclin-
CDK complexes drive the cell through the different phases of the cell cycle as indicated. P21 inhibits the
cyclin-CDK interaction. pHH3 acts as a marker for mitosis.
Each cyclin is also responsible for a different cell cycle transition. Cyclin D activates the
GO-G1 transition, cyclin E promotes the transition between GI and S, cyclin A advances
the transition between S and G2 and cyclin B the progression from G2 to mitosis.
Alterations in cell cycle progression result in unregulated cell growth known as
cancer (Kastan). When the enzymatic activity is too high the cdks detach from their
cyclin. The cyclin and cdk complex activity is modulated by the cell cycle inhibiting
proteins p21, p2 7 and Cdc25. The first stage of the cycle, G1, is regulated by p21 and
p27, which bind to cyclin D/cdk 4 complexes and cause a GO/Gi arrest (Vermeulen).
The p21 protein also moderates the S phase and the G2/M transition. The phosphatase
Cdc25 controls entry and progression through the S phase by removing cdc2 inhibitory
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phosphates (DiPaola, 3311). Many cancers show an over expression of Cdc25
(Kristjansdottir).
Levels of p21 and p27 are controlled by p53 (Maki). p53 is a transcription factor
responsible for regulating the cell cycle. Because of its inhibitory qualities it is also
called a tumor suppressor (IMCB). In response to DNA damage in G1, p53 causes a
G1/S phase arrest allowing the DNA to repair before replication. If the damage is too
significant to be fixed the cell becomes apoptotic (Schafer). Many human cancers have
mutations in p53. When p53 is suppressed or inactivated cells grow at higher rates and
are not checked to ensure proper configurations (Moreno). This causes rapid cell
proliferation, often inducing tumors that result in cancer. In order to ensure that the cell
does not enter mitosis with DNA damage present the checkpoint homologs, Chkl and
Chk2, are used to stop the cycle until the damage has been repaired (Kastan).
Sometimes the DNA damage present in the G2 phase is too significant to be
repaired so the cells remain in an arrested state and do not enter mitosis. This cell cycle
arrest leads to non-dividing cells containing double the amount of DNA (4N). These
arrested cells are called senescent. Senescence is similar to apoptosis because it is a
stress response. Unlike apoptosis it does not result in death, instead halting the cell cycle
to keep cells from proliferating (Serrano). DNA damage, like that occurring during
chemotherapeutic treatments is thought to be a possible cause of cellular senescence
(Campisi, 2005).
One of the chemotherapeutic treatments for cancer is Doxorubicin. This drug
works by inhibiting the protein topoisomerase II (Jarvinenen). Topoisomerase II cuts
both strands of DNA during replication in order to relieve topological stress caused by
the unwinding of the DNA double helix. Doxorubicin stabilizes the topoisomerase after
it has broken the DNA strands, preventing them from re-ligating. This stops DNA
replication from occurring and generates DNA strand breaks. Doxorubicin can cause
both cell cycle arrest and apoptosis when used in different dosages depending on the
severity of the DNA damage (Zhou). Apoptosis can be caused by severe DNA damage
like double stranded breaks while lesser amounts of damage result in cell cycle arrests.
Our goal is to determine how Doxorubicin affects the U20S cell cycle. Our
U20S cells come from the human osteosarcoma U20S cell line. This is one of the most
commonly used cell lines in biology research because its protein expression is well
known (Niforou). Flow cytometry will be used to monitor the progression of treated cells
through the cell cycle. PI-BrdU staining of the U20S cells shows progression through
the cell cycle by monitoring DNA synthesis. Bromo-2'-deoxyuridine (BrdU) is
incorporated into the DNA during replication (S-phase) (Darzynkiewicz). When these
cells are stained with propidium iodide (PI) and run through flow cytometry the
percentage of cells falling into the G1, S and G2/M phases is determined. PI is a marker
for nucleic acids (Molecular Probes). After DNA synthesis the number of nucleic acids
in the cell doubles and this size change is detected and used to monitor cell cycle
progression. This tells us the fraction of replicating cells. We will also monitor cell
cycle arrests using flow cytometric analysis. The amounts of Cyclin B present during
each stage of the cell cycle determines if cells are actively progressing. Cyclin B is
needed to advance from G2 to Mitosis. High Cyclin B levels show cells in G2, while low
levels represent Gl. Cyclin B also monitors senescence. Cells undergoing mitosis are
marked by the presence of pHH3 (phospho-histone H3) (Colman).
We will determine whether the cell has entered apoptosis by simultaneously
monitoring cleaved caspase 3 and cleaved PARP antibodies, both of which are markers
for programmed cell death (Boulares). Monitoring for apoptosis will occur at three time
points (12, 24 and 48 hours). The cell cycle's progression will be monitored at eight
different time points over the span of 48 hours (2,4,8,12,16,24,36,48). This determines
how the DNA damage caused by different dosage levels of Doxorubicin affects the cell
cycle over a fixed set of time. After we have determined where the cell cycle arrests
occur and where apoptosis is most prevalent it will be possible to predict how different
treatments will affect cell cycle arrests and induce cell death.
This research will create a model of treated U20S cells during the cell cycle by
monitoring the cell's progression through each stage. Since we are treating with
Doxorubicin the cell's reaction to the drug will be used to simulate a model of how the
cell reacts. As the dosages are altered and the progression of the cells monitored it is
possible to determine how the level of Doxorubicin affects when the cell decides to arrest
or enter apoptosis. While the cell cycle has been studied in detail this model of the
system allows us to predict how the cell will react to a given treatment before it is
actually administered.
Materials and Methods
Platin2
U20S cells were grown in Dulbecco's Modified Eagle's media supplemented
with 10% Fetal Bovine Serum, 1% Penicillin, 1% Streptomycin and 2 mM Glutamine.
Cells were incubated at 370C in 5% C02. For the experiment 4x10^6 cells were plated
per 15 cm plate. Each time point corresponded to one 15 cm plate.
Doxorubicin Treatment
24 of the plates were used for treatment with luM Doxorubicin with time points
at 2,4,8,12,16,24,36 and 48 hours. The treatments were applied in three doses 2uM,
10uM and Untreated (UN) split evenly among the plates. Four hours into the time course
the media was swapped for DME + 1% FBS, 1% Pen/Strep and 1% Glutamine.
9 plates were used for apoptosis analysis at 12,24 and 36 hour time points. Three
doses of doxorubicin were applied in 2uM, 10uM and Untreated increments to three
plates each.
Ethanol Fixing
The plated cells were harvested and the media was stored on ice in a 50mL Falcon
tube. The cells were washed with 10mL cold PBS and added to the tube of media. 2mL
of trypsin were added to the plate and it was incubated at 370 C for 5 to 10 minutes.
Using the PBS/media mixture the trypsinized cells were washed from the plate and added
to the Falcon tube. The tube was spun down for 5 minutes at 1500 RPM in the swinging
bucket rotor. The supernatant was removed and the cells washed with lmL PBS and
transferred to eppendorfs. The cells were washed again and then resuspended in 80%
EtOH. The tubes are stored at -200 C.
Methanol Fixing
The plated cells were harvested and the media was stored on ice in a 50mL Falcon
tube. 10mL of PBS was used to wash the cells and added to the Falcon tube. The cells
were trypsinized with 2mL of trypsin and incubated at 370 C for 5-10 minutes. The
trypsinized cells were washed with the PBS/media solution and added to the Falcon tube.
The tube was spun down for 5 minutes at 5000 RPM in the swinging bucket rotor. The
supernatant was removed and the cells washed with lmL of PBS then transferred to
eppendorfs. The cells were rewashed with cold PBS and resuspended in 200uL 4%
formaldehyde and incubated for 15 minutes at room temperature. The cells are washed
with PBS and resuspended in 200uL of 100% methanol. The cells are stored at -200 C.
Cell Titer Glo - Viability Testing
100 gtL of ethanol harvested cells were placed in 96 well plates for testing and
equilibrated to room temperature for 30 minutes. The CellTiter-Glo Luminescent
Viability Assay was used. The CellTiter-Glo Buffer was thawed to room temperature.
10mL of Buffer was transferred to the CellTiter-Glo Substrate, reconstituting the
enzyme/substrate mixture, creating the reagent and mixed by vortexing. 100L of reagent
was added to each well, and the contents mixed on an orbital shaker for 2 minutes. Plate
stabilized at room temperature for 10 minutes. Luminescence was recorded.
BrdU/PI Flow Cytometry
20uL of 10mM BrdU was added to the plated cells one hour before harvesting.
After the time course was complete 200uL aliquots of all 24 time points were put into
eppendorfs and spun down for 1 minute at 5000 RPM. The supernatant was removed
and the cells washed with lmL of a PBS-OBB solution containing 50%PBS and 50%
Odyssey Blocking Buffer (OBB). The cells were spun down and incubated in lmL of
2M HCL/0.5%Triton X-100 for 30 minutes at room temperature. The HCI was removed
and ImL of 0. I1M Na2B40 7 pH 8.5 added to each eppendorf and incubated at room
temperature for 2 minutes. The Na2B407 is removed and the cells were washed with lmL
of PBST-OBB containing 50% PBS-Tween and 50% OBB. A primary antibody solution
of 1.3 mL PBST-OBB and 13uL mouse anti-BrdU antibody was made. 50uL of this
solution is added to each eppendorf. The samples are incubated overnight at 40 C. A
secondary antibody solution is made with 1.3mL PBST-OBB and 13uL Goat anti-Mouse
647 antibody and incubated for 1 hour. The cells are washed twice with PBST and then
50uL of the secondary solution was added. The cells incubated 1 hour at room
temperature and were then washed twice. The Propidium Iodide (PI) solution was made
with 10mL PBS, 100uL of 10mg/mL PI and 10uL Sigma RNAse A. 400uL of the PI
solution was added to each tube and they were transferred to flow cytometry tubes and
stored on ice.
Cleaved Caspase 3/ Cleaved PARP Flow Cytometry
Aliquots of 200uL of the apoptosis time points were put in eppendorfs. The cells
were spun down at 5000 RPM for 1 minute and the supernatant removed. The cells were
washed with 200uL PBST. A primary antibody solution was made with 900uL PBST-
OBB, 4.5uL rabbit cleaved caspase3 (BD 559565) and 4.5uL of mouse cleaved PARP
AlexaFlour 647. 50uL of the primary antibody solution was added to each of the
eppendorfs and the samples were incubated overnight at 40 C. The cells were washed
with 200uL PBST. A secondary antibody solution was prepared with 900uL PBST-OBB,
4.5uL goat anti-rabbit 488 IgG (Invitrogen A11008). 50uL of the secondary solution was
added and the cells were incubated overnight at 40 C. The cells were washed,
resuspended in 200uL PBST and transferred to Flow Cytometry tubes.
Cyclin B/ pHH3 Flow Cytometry Analysis
Aliquots of 200 giL of the ethanol fixed U20S cells were added to eppendorfs.
The cells were spun down at 5000 RPM for 1 minute and the supernatant was removed.
The cells were washed with 200 gL PBST. A primary antibody solution was made with
26 ptL rabbit Cyclin B antibody (SC-752) added to 1.3mL PBST-OBB containing 50%
PBS-Tween and 50% OBB. 50 tL of the primary antibody solution was added to each
eppendorf and the cells were incubated overnight at 40 C. A secondary antibody solution
was prepared with 13jiL goat anti-rabbit 488 IgG (Invitrogen A11008) and 1.3mL PBST-
OBB . 50 jiL of this solution was added to the eppendorfs and incubated for 1 hour at
room temperature. The cells were washed and resuspended in 200 AiL PBST. The
Propidium Iodide (PI) solution was made with 10mL PBS, 100uL of 10mg/mL PI and
10uL Sigma RNAse A. 400uL of the PI solution was added to each tube and they were
transferred to flow cytometry tubes and stored on ice.
Flow Cytometry
Flow Cytometry is used to analyze cells suspended in a fluid stream. A beam of
light is passed through the liquid and numerous detectors are aimed at it in order to
analyze the cells in suspension. One is in line with the beam to detect for forward scatter
(FSC) and others are located perpendicular to the flow and used to analyze the side
scatter (SSC). Also numerous fluorescent detectors are present to analyze fluorescent
emissions from staining in the sample. Analyzing the emission peaks from the detectors
relates specific information about the cell. The FSC is used to determine the cell volume
and the SSC determines inner complexities, such as area (BD Biosciences).
A flow cytometer is used to analyze cells at a rapid rate. Using a high-throughput
system the cells are passed through the light beam and monitored by detectors to analyze
the cell's progression through the cell cycle. Antibodies marked by fluorescence are
added to and incorporated into the cell. When the cells are passed through the light beam
the antibody levels are detected. By using antibodies responsible for integral parts of the
cell cycle, i.e. the transition between cell cycle stages or markers for each stage, it is
possible to tell how far progressed each cell is (Flow Cytometry Principles).
The flow cytometry results are then analyzed using a program called FlowJo.
This allows us to change the axes and sort the cells appropriately. The intact cells are
sorted by graphing the SSC vs. FSC. To determine which of the intact cells are single
cells and not groups, the area and the height are compared. The cells can then be
analyzed to determine the specifics of the cell cycle progression.
Results
Treating U20S cells with Doxorubicin in three dosage amounts produces two
distinct results. Analysis after harvesting the cells at eight time points over forty-eight
hours shows a noticeable trend in both the 2 gM and 10 iM treated cells While the
untreated cells grow and divide becoming more confluent the treated cells respond
differently to Doxorubicin. Instead of proliferating the 10 iM U20S cells become
apoptotic, and the 2 jtM cells enter a G2 phase cell cycle arrest (Figure 2).
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Figure 2. Cellular Outcome after Doxorubicin Treatment - Treating U20S cells with doxorubicin
results in either cell cycle arrest or cell apoptosis in a dose dependent manner.
Apoptosis
U20S cells apoptose in response to Doxorubicin (Igney). Apoptosis is monitored
in two ways; by using a cell titer glow assay to determine viability and also by using the
cleavage of Casp3 and PARP as markers of apoptosis. The graph in Figure 3 shows the
results of the Cell Titer-Glo assay.
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Figure 3. Cell Viability Using Cell Titer Glo Assays
This graph compares the cell viability of Untreated, 2 1iM treated and 10 gM treated Doxorubicin cells over
a 48 hour time period.
Over the duration of the time course the percent of untreated viable cells grew. This
shows the cells were still proliferating. The viability levels of the 10 gM treated
Doxorubicin cells had a trend opposite to the untreated, with almost no viable cells after
48 hours. Instead of undergoing mitosis and replicating the high dosage of Doxorubicin
causes apoptosis in 10 gM treated U20S cells. The 2 gM treated cells did not have a
distinct growth or decline in cell viability. This suggests that the cells under went a cell
cycle arrest.
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To determine the percentage of cells undergoing apoptosis after treatment with 2 pM and
10 jtM doxorubicin compared to untreated cells, flow cytometry analysis was done using
Caspase 3 and PARP (Poly ADP ribose polymerase). Apoptosis levels were monitored
using the cleavage of Caspase 3 and PARP. Both Caspase 3 and PARP are markers for
programmed cell death or apoptosis (Boulares). The methanol fixed U20S cells (12, 24
and 48 hours) were marked with cleaved Caspase 3 (cCasp3) and cleaved PARP
(cPARP). Figure 4 shows the flow cytometry results at 24 hours (entire time course in
appendix 1).
cCasp3 and cPARP at 24hours
SSC vs. FSC cPARP vs. cCasp3
UN
2uM
10uM
Figure 4. U2OS cells apoptose after treatment with doxorubicin.
Cleavage of caspase 3 and PARP was monitored by flow cytometry. The left panel shows the side scatter
vs. forward scatter plot. Gating of intact cells is shown (circle). The right panel shows the cleaved PARP
vs. cleaved caspase 3 plots. Cells positive for both cCasp3 and cPARP (upper right quadrant) are
apoptotic.
As the dosage of Doxorubicin increased the number of cells positive for both cleaved
Casp3 and cleaved PARP increased, as can be seen in the upper right quadrant of the
cPARP vs. cCasp3.
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The increased percentage of cells entering apoptosis can be seen in Figure 5.
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Figure 5. Graph of cCasp3 and cPARP over 48 hours - This graph compares the amount of cell death at
12, 24 and 48 hour time points for the three dosage amounts - UN, 2uM and 10uM.
The readings were taken at three time points - 12, 24 and 48 hours. The untreated cells
have the lowest percentage of apoptosis with only 5% of cells becoming apoptotic after
48 hours. This could be due to overcrowding on the plates when the cells became too
confluent. The 2pM cells show little change over the 48-hour time course. This suggests
that the cells undergo some sort of arrest, preventing them from replicating but resulting
in a fate other than cell death. The 10 giM cells show a constant increase in the
percentage of apoptosed cells. From 12 hours on the percentage of cells positive for both
cCasp3 and cPARP is over 17%. This is three times higher than the other treatments.
This leads us to believe that U20S cells are not able to recover from such a high dosage
of Doxorubicin.
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Cell Cycle Arrest
U20S cells treated with 2jtM Doxorubicin do not only apoptose, but also cease
replicating because of a cell cycle arrest. To monitor the progression of the cells through
each phase of the cell cycle the U20S cells were treated with BrdU one hour before
harvesting to allow for incorporation. The level of incorporation after this addition was
monitored by flow cytometry analysis of the harvested cells using PI staining. PI staining
monitors nucleic acid levels in the cell (Molecular Probes). As cells go through the cell
cycle and DNA is synthesized, the amount of nucleic acid present doubles. Staining with
PI shows this growth and allows grouping of the cells based upon cell cycle phase. This
progression of the cells and the gating for analysis at 24 hours is seen in Figure 6 (entire
time course in appendix 2).
Cell Cycle Arrest shown by PiUBrdU at 24 hours
SSC vs. FSC P1 histogram BrdU vs. Pl
UN
2uM
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Figure 6. Cell Cycle Arrest shown by PI-BrdU analysis at 24 hours.
To monitor progression through the cell cycle cells incorporation of BrdU and DNA content were
monitored by flow cytometry. The left panel shows gating (circle) for intact cells. The center panel shows
the levels of PI incorporation. The right panel shows the percent of cells in each phase of the cell cycle.
Data for cells harvested 24 hours after treatment is shown. Cells treated with 2 gLM Doxorubicin exhibit apronounced arrest in the G2 phase of the cell cycle.
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The left panel shows the selection of intact cells similar to the gating in Figure 4. This
gating allows us to separate apoptosed cell particulates from the intact cells still
progressing through the cell cycle. The right hand panel shows the cells' progression.
BrdU is incorporated during the S phase, so cells still undergoing DNA synthesis
show increased BrdU levels. All three of the dosage amounts show an uptake of BrdU
during the S phase, but the 10 gM cells have a lower percentage of cells actively
synthesizing new DNA. While the untreated cells show a normal progression between
the phases, the 2 jM cells exhibit a pronounced arrest during the G2 phase. The cells are
undergoing synthesis, as can be seen by high levels of BrdU incorporation, but are not
dividing. The cell cycle arrest over time is shown in the graphs in Figure 7.
Percent U2OS Cells in Each Phase Stained with PI-BRDU
Untreated Cls
ii
U
T2u (Doxoru
2uM Doxorubikin
S
e D(xorubcns)
lOuM Doxorubicin
I.
Figure 7. U20S cell cycle dynamics after doxorubicin treatment.
Untreated cells (upper panel) rise in GI with increasing time. 2 tM cells (center panel) rise in G2. 10 pM
cells show no significant growth or declines after 8 hours.
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The top graph shows the percentage of untreated cells in each phase of the cell cycle over
the 48 hour time period. The number of cells in Gl increases as time goes on, showing
that cells have replicated, divided and are reentering the cell cycle. The 2 pM cells in the
center panel exhibit the G2 arrest starting at 24 hours, where the percentage of cells in G2
increases at a constant rate, while the percentage of cells in Gl declines slightly and S
declines at a rapid pace. The cells are reaching the G2 stage and undergoing a cell cycle
arrest. This is caused because there is enough DNA damage to halt the cell's progression
through the cycle, but the damage is not severe enough to result in apoptosis. This also
shows that the 2 gpM treatment's effect on the cell cycle is less harsh than the 10 pM,
shown in the bottom graph. At this dosage the cells remain constant in GI and G2 with a
lower percentage in S because the cells are too damaged to be repaired and enter
apoptosis.
G2 Phase and Mitosis
Cyclin B works with CDK1 to progress the cell from the G2 phase to mitosis.
High cyclin B levels show that the cell is currently in the G2 phase. Analysis by flow
cytometry using the ethanol fixed U20S cells with Cyclin B as a marker for G2
determines what stage of the cell cycle the cells are in. This is shown for the 24 hour
treatment in Figure 8 (entire time course in appendix 3).
Cell Cycle Arrest Analysis using Cyclin B at 24 Hours
UN
2uM
10uM
Figure 8. Cyclin B levels drop in U2OS cells arrested in G2 after 2 AiM Doxorubicin treatment.
The upper panel shows Cyclin B level plotted against PI staining for untreated U20S cells. Cyclin B is low
in Gl, increases through S phase and peaks in G2. Cells arrested after treatment with 2 giM doxorubicin
develop a population that is 4N but low in cyclin B. Cells treated with 10 tM doxorubicin do not show the
normal progression through the cell cycle, with a large portion below the G1 phase.
The lower left quadrant shows low Cyclin B levels, which is expected since progression
through Gl is controlled by Cyclins D and E. As the cell cycle continues into S and G2,
the Cyclin B levels increase, as can be seen in the upper right hand quadrant. This shows
more cells being trapped in the G2 phase. The percentage of cells in G2 is much higher
in the 2 tM Doxorubicin treated cells than the untreated. The 10 gpM cells have a lower
percentage of cells positive for Cyclin B with most cells accumulating below the Gl
phase. These cells are apoptotic.
The 2 p.M treated cells show an accumulation of cells in the G2 phase that are not
positive for Cyclin B. This lack of Cyclin B means the cells will not progress into
mitosis completing the cell cycle, instead remaining in the G2 stage as 4N cells. This halt
in progressions is called senescence. When cells become senescent they enter a
permanent cell cycle arrest. In this study the cells enter senescence because the 2 p.M
Doxorubicin has caused significant DNA damage, but unlike the 10 9M treatment is not
severe enough to result in apoptosis.
Another marker to show that Doxorubicin treated U20S cells fail to enter mitosis
is shown using pHH3 as a marker during flow cytometry. Positive levels of pHH3
indicate the cells are mitotic (Colman). Figure 9 shows the 24 hour untreated, 2 gM
treated and 10 jtM treated cells after analysis with pHH3 (entire time course in appendix
4).
Mitosis Levels in Treated U20S Cells
UN
2uM
10uM
Figure 9. pHH3 Levels Identify Cells in Mitosis at 24 hours.
pHH3 is a marker in the cell cycle for cells going through mitosis. The top box shows the number of
untreated cells in mitosis (pink ring). The middle box shows 2 giM cells and the lower box 10 gM cells,
neither of which show signs of mitosis.
While the untreated cells have a small percentage of cells in mitosis they show a
steady cell progression compared to the 2 [iM and 10 iM cells. The Doxorubicin treated
cells' lack of pHH3 expression shows that advancement through the cell cycle has
ceased. The 2 jiM cells have entered cellular senescence while the 10 gM cells have
undergone apoptosis.
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Treatment with Doxorubicin in different dosages has two possible responses in
U20S cells. These different results are shown in Figure 10.
2uM Doxorucin
G2 Afrest
Figure 10. Doxorubicin Treatment Results - Treating U20S with 2uM Doxorubicin results in a
permanent cell cycle arrest in the G2 phase. Treating cells with 10uM Doxorubicin results in cell
apoptosis.
When the cells are treated with a low (2 [M) dosage of Doxorubicin, they exhibit a G2
phase cell cycle arrest. The low Cyclin B levels seen in these cells show cellular
senescence. The 10 pLM treated cells suffer too much DNA damage to simply undergo a
G2 arrest. The PI/BrdU staining shows a decrease in synthesis levels for these cells.
Cells treated with a high dosage of Doxorubicin (10 pM) are no longer able to replicate
their DNA. Instead these cells become apoptotic. For both the 2 [pM and 10 gM
treatments the cells are no longer capable of proliferation.
Discussion
U20S cells treated with Doxorubicin either apoptose or enter a cell cycle arrest.
The cell's outcome depends on the level of Doxorubicin administered. Cells treated with
the higher level, 10 [pM, cease replicating and enter apoptosis. These cells have sustained
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a level of DNA damage too high to repair. A lower dosage of 2 jiM does not cause cell
death, instead resulting in a G2/M cell cycle arrest. In 2 gLM cells this arrest is permanent
and is referred to as cellular senescence. Senescent cells do not apoptose and instead are
removed by natural killing cells (Serrano).
Analysis using cCasp3 and cPARP shows a significant increase in apoptosis for
cells treated with 10 pM Doxorubicin over the 48 hour time period. The untreated and 2
pgM treated cells do not have this high percentage of cell death. Instead of entering
mitosis the cells undergo programmed cell death. This is caused by increased amounts of
DNA damage. The data also shows a decreased level of synthesis in the 10 pM treated
cells. This is seen in Figure 6's flow cytometry analysis of the BrdU levels versus PI
staining. The lower number of cells going through synthesis means that the Doxorubicin
is inhibiting Topoisomerase II (Jarvinen). Topoisomerase II is responsible for religating
the two strands of DNA and when inhibited synthesis is stopped. When Doxorubicin is
administered in high dosages the cells cannot repair the damage caused by the
inactivation of Topoisomerase II and enter apoptosis.
The 2 p.M synthesis levels were lower than the untreated cells but the cells were
not damaged severely enough to become apoptotic. Instead, the cells enter an arrested
state during the G2 phase of the cell cycle. The G2 phase is one of the checkpoints for
cellular progression as monitored by Chkl and Chk 2. If the cells exhibit DNA damage,
replication is halted allowing time for DNA repair to occur. In the 2 tpM treated cells,
damage is not repaired and the process is permanently halted. Arrested cells accumulate
in the G2 phase as seen in the BrDU vs. PI graphs shown in Figure 7. The cells are too
damaged to go through mitosis and replicate, but not damaged enough to apoptose.
Analysis using Cyclin B vs PI staining gives a clearer view of how the 2 AiM cells
arrest. Cyclin B is responsible for the cell's progression through the G2 phase and into
mitosis. The cell's location in the cell cycle is shown by analysis with Cyclin B
antibodies, the cell's place in the cell cycle is shown, as shown in Figure 8. The
untreated cells show a normal progression, with cells starting with low levels of Cyclin B
in GI that rise as the cells enter G2 and mitosis. The 2 tM cells have a different
progression. The earlier time points show the cell's normal advancement from G1 to G2
with an elevated incorporation of Cyclin B in the G2 phase. As the time points progress,
the cells enter the G2 phase but lack the positive Cyclin B levels.
Decreased Cyclin B levels mean that the cell is unable to progress further into
mitosis. These cells are not apoptotic, instead stuck in a permanent G2 arrest. This arrest
has cells with double the amount of DNA (4N) and the cells are referred to as senescent.
Senescent cells are a stress response to DNA damage. Our data shows that 10 tM
treatments are too high to cause cellular senescence, but the 2 tM treatments cause
enough DNA damage to result in a permanent cell cycle arrest but avoid apoptosis.
Senescence, like apoptosis, is an effective method of treating cancer. When cells become
senescent tumor growth ceases. When progression stops, the tumor cells are attacked by
neutrophils, macrophages and other killer cells within the body. These eventually destroy
the halted tumor cells (Serrano). This means that higher dosages of Doxorubicin are not
necessarily needed in chemotherapeutic treatments.
The PI vs BrdU flow cytometry analysis showed the levels of synthesis over the
48 hour time course, allowing comparisons between the different treatment levels.
Similar to the 10 jiM treatments the 2 jiM cells also show a decrease in synthesis levels
over time, just declining at a slower rate than the stronger dosage. The FlowJo gating
grouped the cells into the different cell cycle phases. This shows accumulation of
untreated cells in Gi, 2 jM in G2 and a low level of synthesis for the 10 jM treated
cells.
Treatment resulting in apoptosis and cell cycle arrest means the cells are not
progressing through mitosis. The percentage of cells still replicating is shown using
pHH3, and after Doxorubicin is added the treated cells show little to no mitotic cells.
This reinforces that both dosages of Doxorubicin are successful in halting the cell's
progression by inhibiting replication of damaged cells. While the 2 iM and 10 jM
treatments aid in tumor regression they do so via different methods. During apoptosis the
cells die quickly, and the cell's contents are cross-linked and removed by scavenging
cells. This means that inflammatory reactions do not occur (Campisi, 339). As
previously stated, cells in a fixed arrest state are consumed by macrophages and other
killer cells.
Cancer cell proliferation and growth occurs when damaged cells are able to
replicate in large amounts (Campisi, 2005). Doxorubicin is able to control how the cells
progress through the cell cycle and even inhibit growth and replication. Over the 48-hour
time period, U20S cells treated with 10 iM Doxorubicin went from a level of high
confluence at the start of treatment, to low viability with over 25% of the cells positive
for cCasp3 and cPARP, signaling apoptosis. The synthesis levels were also significantly
reduced during 10 pM treatments. The high levels of apoptosis and low levels of
synthesis show that at high dosage levels cells cannot properly function or repair DNA
because the damage is too severe.
While the high treatment levels resulted in apoptosis, other inhibitory effects
caused by Doxorubicin occurred after the 2 CtM treatments. U20S cells treated with this
lower dosage amount were seen to undergo a permanent G2 arrest called cellular
senescence. These senescent cells have 4N DNA, as shown by PI staining, but do not
have positive levels of Cyclin B, the normal marker for G2 progression. With a lack of
Cyclin B the cells are unable to leave the G2 phase and enter mitosis. This inability to
enter mitosis is further validated by the pHH3 data where little to no cells progressed
through mitosis. Cellular senescence is an effective break on tumor progression, because
naturally occurring cells remove the cancerous ones, and the permanent halt acts as a
successful stop to proliferation (Serrano).
While the processes of apoptosis and cellular senescence are very different, they
are controlled through the same regulatory mechanisms. Both processes are monitored
by the p53 and Rb pathways (Campisi, 2003). The p53 pathway is responsible for
regulation by starting the transcription of important genes. The Rb pathway is actually
responsible for controlling the cell cycle's progression and therefore regulates cellular
senescence. Because the Rb and p53 pathways overlap at times, Rb is also responsible
for apoptosis. The p53 protein is also very important in sensing stress (Serrano). Since
tumors are stressful environments the p53 regulatory system is needed to monitor cellular
stress and ensuing DNA damage.
These results show that it is possible to stop cellular progression through the cell
cycle using two different methods to halt cell proliferation. The two responses are
controlled by the dosage of Doxorubicin applied to the cells. 2 giM treatments are
capable of preventing the cells from replicating by holding them in the G2 phase. These
senescent cells lack Cyclin B, which allows them to enter into mitosis, and therefore
remain in a stable arrested state. When the dosage level is increased to an amount of 10
tiM a significant level of DNA damage occurs, resulting in apoptosis. While these
different treatment options both halt the cell's progression they use different mechanisms
of action to produce this same result. Cells that apoptose have undergone programmed
cell death and lost all cell viability. Senescent cells are intact cells in the 4N stage that
are unable to enter mitosis and proliferate. Scavenging cells take care of the dead
apoptotic cells while Natural killer cells consume the senescent cells.
U20S cells treated with Doxorubicin in either 2 jpM or 10 jtM dosages experience
a stop in cell proliferation. For the 2 tM cells, the DNA damage is not severe enough to
cause apoptosis and the cells enter a permanent G2 phase arrest called senescence. These
senescent cells lack Cyclin B and are unable to enter mitosis. Administering a 10 pM
dose of Doxorubicin to U20S cells inhibits the ligase activity of Topoisomerase II and
causes apoptosis. Both treatments stop cellular replication causing a halt in tumor growth
and therefore might act as successful stops in cancer development.
References
BD Biosciences. Introduction to Flow Cytometry - A Learning Guide. San Jose, CA.
April 2000.
Bihani, Teeru, Douglas X. Mason, Tonya J. Jackson, Shang Chiug Chen, Benhamin
Boettner and Athena W. Lin. Differential Oncogenic Ras Signaling and
Senescence in Tumor Cells. Cell Cycle 3:9, 1201-1207. September 2004.
Boulares, A. Hamid. Alexander G. Yakovlev, Vessela Ivanova, Bogdan A. Stoica,
Geping Wang, Sudha Iyer and Mark Smulson. Role of Poly(ADP-ribose)
Polymerase (PARP) Cleavage in Apoptosis. J Biol Chem. Vol. 274, Issue 33.
932-940. August 1999.
Campisi, Judith. Suppressing Cancer: The Importance of Being Senescent. Perspectives.
Science. Vol. 309. 86-887. August 2005.
Campisi, Judith. Cancer and Ageing: Rival Demons?. Nature Reviews-Cancer. Vol 3.
339-347. May 2003.
Colman, Howard. Caterina Giannini, Li Huang, Javier Gonzalez, Kenneth Hess, Janet
Bruner, Gregory Fuller, Lauren Langford, Christopher Pelloski, Joann Aaron,
Peter Burger, Ken Aldape. Assesment and Prognostic Significance of Mitotic
Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-
grade Infiltrating Astrocyvtomas. American Journal of Surgical Pathology. 657-
664. May 2006.
Darzynkiewicz, Zbigniew, Xuan Huang, Masaki Okafuki. Detection of DNA Strand
Breaks by Flow and Laser Scanning Cytometry in Studies of Apoptosis and Cell
Proliferation (DNA Replication). Methods Mol Biol. 81-93. 2006.
Dipaola, Robert S. To Arrest or Not to G2-M Cell-Cycle Arrest. Clinical Cancer
Research. Vol 8. 3311-3314. 2002
Flow Cytometry Principles. Berkeley Biology Department. Online. Internet. Available
http://biology.berkeley.edu/crl/flow cytometry basic.html
Igney, Frederik K. and Peter H. Krammer. Death ad Anti-Death: Tumour Resistance to
Apoptosis. Nature Reviews-Cancer. Vol.2. 277-288. April 2002.
Jarvinen, Tero A.H., Minna Tanner, Virpi Rantanen, Maarit Barlund, Ake Borg, Seija
Grenman, and Jorma Isola. Amplification and Deletion of Tompoisomerase IIa
Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II
Inhibitor Doxorubicin in Breast Cancer. American Journal of Pathology. Vol. 156
No.3. March 2000.
Kastan, Michael B. and Jiri Bartek. Cell-cycle Checkpoints and Cancer. Nature
Publishing Group. 2004.
Kristjansdottir, K and J Rudolph. Cdc25 Phosphatases and Cancer. Chem Biology. 1043-
1051. August 2004.
Maki, Carl G and Peter M. Howley. Ubiquitination of p53 and p21 is Differentially
Affected by Ionizing and UV Radiation. Molecular and Cellular Biology. p 355-
363. January 1997.
Medical News Today. US Cancer Deaths Fall Second Year in a Row Despite Growing
Age and Population. Medical News Online. January 18 2007. Available
http://www.medicalnewstoday.com/articles/61090.php
Molecular Probes. Propidium Iodide Nucleic Acid Stain. Molecular Probes Inc. Eugene,
OR. 1999
Moreno, Carlos S., Lilya Matyunina, Erin B. Dickerson, Nina Schubert, Nathan J.
Bowen, Sanjay Logani, Benedict B. Benigno, John F. McDonald. Evidence that
p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian
Carcinomas. Plosone - Issue 5. May 2007.
National Cancer Institute. Questions and Answers About Chemotherapy. Online. Internet
Available http://www.cancer. gov/cancertopics/chemotherapy-and-you/page2
Niforou, KM, Anagnostopoulos, AK, Vougas, K, Kittas, C, Gorgoulis, VG, Tsangaris,
GT. The Proteome Profile of the Human Osteosarcoma U20S Cell Line. Cancer
Genomics Proteomics. 63-78. Jan-Feb 2008.
P53 Knowledgebase. Lane Group at the Institute of Molecular and Cell Biology (IMCB).
Online. Internet. Available http://p53.bii.a-star.edu.sg/
Schafer, K. A. The Cell Cycle: A Review. Vet Pathology :461-478. Wyeth-Ayerst
Research. 1998.
Senderowicz, Adrian M. Small-molecule Cyclin Dependent Kinase Modulators.
Oncogene 22: 6609-6620. Nature Publishing Group. 2003.
Serrano, Manuel Ph.D. Cancer Regression By Senescence. Clinical Implications ofBasic
Research. The New England Journal of Medicine. May 2007.
Vermeulen, Katrien, Dirk R. Van Bockstaele and Zwi N. Berneman. The cell cycle: a
review of regulation, deregulation and therapeutic targets in cancer. Cell
Proliferation 36: 131-149. 2003.
Zhou, Muxiang, Lubing Gu, Fengzhi Li, Yerun Zhu, William G. Woods and Harry W.
Findley. DNA Damage Induces a Novel p53-Survivin Signaling Pathway
Regulating Cell Cycle Apoptosis in Acute Lymphoblastic Leukemia Cells. The
Journal of Pharmacology and Experimental Therapeutics. 2002.
APPENDICES
Appendix 1. pages 30-32
Flow cytometry results for Apoptosis using cCasp3 and cPARP
Appendix 2. pages 33-44
Flow cytometry results for cell cycle analysis using PI vs. BrdU staining
Appendix 3. pages 45-49
Flow cytometry results for G2 senescence using Cyclin B staining
Appendix 4. pages 50-51
Flow cytometry results monitoring mitosis using pHH3
1.22.08_Dox.1
_cCasp3.cPARP.jo Layout: Dox.1
_cCasp3.cPARP
104
103
102
10
200 400 600
FSC-H
Ungated
1.Dox.1_cCasp3.cPARP_UN_12
Event Count: 30129
800 1000
............ I
200 400 600 800 1000
FSC-H
Ungated
2.Dox.1 _cCasp3.cPARP_UN_24
Event Count: 30228
0 200 400 600
FSC-H
Ungated
3.Dox.l_cCasp3.cPARP_UN_48
Event Count: 30437
1/22/08 11:36 AM
SI . .' '
800 1000
02
101
103
100 101 102
FL1-H: cCasp3
intact cells
1.Dox.1_cCasp3.cPARP_UN_12
Event Count: 29720
104
103
0-2n-
0102
.10U-
101
100 101 102
FL1-H: cCasp3
intact cells
2.Dox.l_cCasp3.cPARP_UN_24
Event Count: 29799
104
10 3
a.
010 210-4
101
100 101 102
FL1-H: cCasp3
intact cells
3.Dox. lcCasp3.cPARPUN_48
Event Count: 29826
(FlowJo v6.4.7)
L~''I 1
10310
1020-
10
103 104
103 104
103 104
103
02
101
0.31
98.6 ". 0.04i
-····---·-·-·------- 
--
1.07
';
..
... 
.'
~.
0.04I ."... ' I" . I. 'I ".
• :,
i:t.
~·-
: ·· .. :
. " " I " , ' I ' I' I
Page 1 of 3
1.22.08_Dox. l_cCasp3.cPARP.jo
10
103
02
10
200 400 600 800 1000
FSC-H
800 1000
Ungated
4.Dox.1_cCasp3.cPARP_2uM_12
Event Count: 30208
103
102
10
0 200 400 600
FSC-H
Ungated
5.Dox.1_cCasp3.cPARP_2uM_24
Event Count: 30376
103
102
10
200 400 600
FSC-H
Ungated
6.Dox.1_cCasp3.cPARP_2uM_48
Event Count: 30585
1/22/08 11:36 AM
8I ' I
800 1000
100 101 102
FL1-H: cCasp3
intact cells
4.Dox.1_cCasp3.cPARP_2uM_12
Event Count: 29736
1U
103
a0
a-
S102
101
FL1-H: cCasp3
intact cells
5.Dox.1_cCasp3.cPARP_2uM_24
Event Count: 29929
104
103
a-
1,2
.10
,.
100 101 102
FL1-H: cCasp3
intact cells
6.Dox.l_cCasp3.cPARP_2uM_48
Event Count: 29705
(FlowJo v6.4.7)
Layout: Dox.1_cCasp3.cPARP
103 104
103 104
-1
-,4
. " . I " " I I I " * I I
I
'
*''
:. .. ;r ·· · · ''
,..o •
'
Page 2 of 3
1.22.08_Dox. 1_cCasp3.cPARP.jo
103
102
10
0 200 400 600
FSC-H
Ungated
7.Dox.1_cCasp3.cPARP_10uM12
Event Count: 30759
800 1000
-
100 101 102
FL1-H: cCasp3
intact cells
7.Dox.1_cCasp3.cPARP_10uM12
Event Count: 29893
Layout: Dox.l_cCasp3.cPARP
103 104
. . . . . . . . . . . . .I I' " ''
0 200 400 600 800 1000
FSC-H
Ungated
8.Dox.1_cCasp3.cPARP_10uM24
Event Count: 30819
I
) 10
10-
200
200
I I , I
400 600
FSC-H
Ungated
9.Dox.1_cCasp3.cPARP_10uM48
Event Count: 30836
1/22/08 11:36 AM
800 1000
FL1-H: cCasp3
intact cells
8.Dox.1_cCasp3.cPARP_1 0uM24
Event Count: 30040
104
103
a
102
101
i no
100 101 102
FL1-H: cCasp3
intact cells
9.Dox.1_cCasp3.cPARP_10uM48
Event Count: 29890
(FlowJo v6.4.7)
1U
103
a.
210
10
10
0
104
103
102(0o
101
In o
___________________________________________ I
103 104
' ''·
104
10
3
a.
10 2
-J
101
100
-
?r- ··. ·
8~' · ·
* ' I * * * I ' * * I ' * ' I ' ' ' I
,4
''
r~Sk.
crs':
·- ~··.: .
·f·- ··:
iv
-
. . , . . . ... . I
Page 3 of 3
9.27.07_BrdUUN.jo Layout-Batch
104
103
102
101
100
0 200 400 600
FSC-H
Ungated
1.BrdU.PI_UN_2
Event Count: 38277
"-4
1U
103-
6 102(0
101
100
0 200
Ungated
2.BrdU.PI UN 4
Event Count: 42699
800 1000
800 1000
400 600 800
FSC-H
1000
1500
I UUU
500
0 200 400 600
FL3-H: PI
singlets
1.BrdU.PI_UN_2
Event Count: 29944
1500
-1000
500
0
0 200 400 600
FL3-H: PI
singlets
2.BrdU.PI_UN_4
Event Count: 30012
10 -
10 -
101
100
800 1000 0 200 400 600
FL3-H: PI
singlets
1.BrdU.PI_UN_2
Event Count: 29944
103
102
10
800 1000
800 1000
.IIII 
I III
0 200 400 600 800 1000
FL3-H: PI
singlets
2.BrdU.PI_UN_4
Event Count: 30012
( Page 1 of 4
S i.' .. . ..
• ' . ' "" '"..., .
.21.2
IA J
',. 2 8• -
.19.6'
.23.7mi·'
.......... VT1 ·_· · · ·
' ' ' I ' ' ' I ' ' ' I ' ' " I " ' "_·___·_·_________
rnnn
' ' I ' ' '
.·
11/13/07 10:27 AM (FlowJo v6.4.7)
9.27.07_BrdUUN.jo Layout-Batch
IU
10 3
10 2
10
S10
0 200 400 600
FSC-H
Ungated
3.BrdU.PI UN 8
Event Count: 41242
IU
10 3
6102
101
100
0 200 400 600
FSC-H
Ungated
4.BrdU.PIUN_12
Event Count: 41555
800
800 1000
800 1000
1500
1UUU
500
0
0 200 400 600
FL3-H: PI
singlets
3.BrdU.PI UN 8
Event Count: 30008
1500
( 1000
500
0
0 200 400 600
FL3-H: PI
singlets
4.BrdU.PI UN_12
Event Count: 29985
800 1000 0 200 400 600
FL3-H: PI
singlets
3.BrdU.PI_UN_8
Event Count: 30008
103
102 -
10
100
800 1000 0 200 400 600
FL3-H: PI
singlets
4.BrdU.PI_UN 12
Event Count: 29985
1 Page 2 of 4
800 1000
I 1117 T rl tr 'rI
800 1000
· · ,I_,_
4
^^^
Iv
1 1 i l 
' I
4
-' '-
.[
'
.,.-···:· · ·
'·:· · · ·
· · · · ·
,.iz . - ·.
··· ·
·
·
.'··.·k0.26:
~t·" ~
- · ·-
rs" I
11/13/07 10:27 AM (FlowJo v6.4.7)
9.27.07_BrdUUN.jo Layout-Batch
10 3
102
.
Ungated
5.BrdU.PI_UN_16
Event Count: 36818
200 400 600 800 1000
FSC-H
2000
1500
1UUU
500
0
0 200 400 600
FL3-H: PI
singlets
5.BrdU.PI UN_16
Event Count: 30018
104
103
I102
LL
10
100
800 1000 0 200 400 600
FL3-H: PI
singlets
5.BrdU.PI UN_16
Event Count: 30018
101
10010" -
0 200 400 600
FSC-H
Ungated
6.BrdU.PI UN 24
Event Count: 34729
800 1000
2500
2000
I UU
1000
500
0 200 400 600
FL3-H: PI
singlets
6.BrdU.PIUN_24
Event Count: 29979
104
10310
102
10
800 1000
.·· 
· · I · I · I
0 200 400 600 800 1000
FL3-H: PI
singlets
6.BrdU.PIUN 24
Event Count: 29979
I Page 3 of 4
800 1000
:' ~:::·:
:i:··. :
:r · · ·:'
·~:' '
.. : I.
· · ·
7
. . . . . . . - I ý . -V r . I
--
·--- · ·------------ ·--- · -
· · · ·- · · ·-
j
_
'AAA
[
A .
1 I I ) I I ) rilll
11/13/07 10:27 AM (FlowJo v6.4.7)
71,:%, ....=; c· .. ..
: 42.5
S 0.22" .
15.7 
-
?37.6"
.[:_ •.
9.27.07_BrdUUN.jo Layout-Batch
102
10 7
0 200 400 600
FSC-H
Ungated
7.BrdU.PI UN 36
Event Count: 46358
800
800 1000
2500
2000
1500
1000
500
0
0 200 400 600
FL3-H: PI
singlets
7.BrdU.PI 
_UN_36
Event Count: 29954
800 1000
I6
COC')
"1-
I -
102-
101
0 200
Ungated
8.BrdU.PI UN 48
Event Count: 52500
400 600
FSC-H
800 1000
3000 -
-i22000
-
1000 -
0-
0 200 400 600
FL3-H: P1
singlets
8.BrdU.PI UN_48
Event Count: 29920
103
102
101
10n
800 1000 0 2
singlets
8.BrdU.PI UN_48
Event Count: 29920
00 400 600 800 1000
FL3-H: PI
11/13/07 10:27 AM
0 200 400 600 800 1000
singlets
7.BrdU.PI_UN_36
Event Count: 29954
FL3-H: PI
103
3
10
10
100- .I, _·1 · _
(FlowJo v6.4.7)
". . " ".
. ~ ~ ~ ~ ' .. .. "•.••.
,~9. - • •...
;-.·
: .o
15..
5. 5.0 5 ' 0 : • ....
· · 15B~
•fY
j
,4
-I H
1
1 s 
a
l I 
I
'
14
' '
' '
i0I
Page 4 of 4
9.27.07_BrdU_2uM_Dox.jo Layout-Batch
104
103
-r-
10
O 1 02
10
100
0 200 400 600
FSC-H
Ungated
1.Dox.TNFBrdU.PI_2uM 2
Event Count: 36435
104
103
"10 2
101
100
0 200 400 600
FSC-H
Ungated
2.Dox.TNF_BrdU.PI_2uM_4
Event Count: 37423
3000-
2000-
1000-
0-
800 1000 0 200 400 600
FL3-H: PI
singlets
1.Dox.TNF_BrdU.PI_2uM_2
Event Count: 30058
3000
2000
1000
A
800 1000 0 200 400 600
FL3-H: PI
singlets
2.Dox.TNF_BrdU.PI 
_2uM_4
Event Count: 30037
800 1000
=
0 200 400 600 800 1000
FL3-H: PI
singlets
1.Dox.TNF_BrdU.PI 2uM 2
Event Count: 30058
10 4
10
3
i±102
101
10o
800 1000 0 200 400 600
FL3-H: PI
singlets
2.Dox.TNF BrdU.PI 2uM_4
Event Count: 30037
11/13/07 10:38 AM
U
10 4
10 -
102
LL
101
S0
...................... I
800 1000
40./'-LJ,,I
I *
l ' I . I 'I 
.' i I ' I i I
IU'
10
''' Iv
.~· .
:·
' ' I I ' I ' ' ' I ' ' ' I ' ' ' I
-
, I ' ' I ' I ' I '
Page 1 of 4 (FlowJo v6.4.7)
in
J28.3 .
Q 0.47
46.1- -
" :
9.27.07_BrdU_2uMDox.jo Layout-Batch
104
103
I
102
10
100
0 200 400 600
FSC-H
Ungated
3.Dox.TNF BrdU.PI 2uM_8
Event Count: 34964
3
10 -
S102U)
10
100-
0 200 400 600
FSC-H
Ungated
4.Dox.TNF_BrdU.PI_2uM_ 12
Event Count: 42284
2500
2000
$1500
1000
500
0
800 1000 0 200 400 600
FL3-H: PI
singlets
3.Dox.TNF_BrdU.Pl_2uM_8
Event Count: 29914
(,
0
2000 -
1500 -
1000-
500
0-O
800 1000 0 200 400 600
FL3-H: PI
singlets
4.Dox.TNF_BrdU.PI_2uM_ 12
Event Count: 30022
10 4
-. 31
101
100
800 1000 0 200 400 600
FL3-H: PI
singlets
3.Dox.TNFBrdU.PI_2uM 8
Event Count: 29914
104
10 3
110 2
.J
101
100
800 1000 0 200 400 600
FL3-H: PI
singlets
4.Dox.TNF BrdU.PI 2uM_ 12
Event Count: 30022
11/13/07 10:38 AM
2. 9 , ;
e.. '~~: 018
18.5
0.53 .
34.b-
.rp.;2
K A
" .
800 1000
800 1000
1.38
1111 I I-I I-III IIIII I Il I
'
"
~
IV~
I . ' I ' ' I I I I . F I
.- 4 ··ll
''
'',' 2
°··:r ·
I I I ' ' ' I ' ' ' I ' ' ' I ' ' ' II " " " I " " " .I " "
A Page 2 of 4 (FlowJo v6.4.7)
9.27.07_BrdU_2uM_Dox.jo
Layout-Batch
104
103
102
10
100
0 200 400 600
FSC-H
Ungated
5.Dox.TNFBrdU.PI 
_2uM_ 16
Event Count: 38418
1U -
10
6102
-1-
101
0n
200 400 600 800 1000
FSC-H
C
Ungated
6.Dox.TNF BrdU.PI 2uM_24
Event Count: 40114
11/13/07 10:38 AM
800
600
4UU
200
0
800 1000 0 200 400 600
FL3-H: PI
singlets
5.Dox.TNF BrdU.PI 2uM_16
Event Count: 29165
1200
900
600
300
0
0 200 400 600
FL3-H: PI
singlets
6.Dox.TNF_BrdU.PI_2uM_24
Event Count: 28547
1
Iv
800 1000
I ' 1V I I
0 200 400 600
FL3-H: PI
singlets
5.Dox.TNF BrdU.PI 2uM 16
Event Count: 29165
104
103
+ 102
101
100
800 1000 200 400 600 800
FL3-H: PI
singlets
6.Dox.TNF BrdU.PI 2uM_24
Event Count: 28547
(FlowJo v6.4.7)
104
10 3 -
2
10
10
10
0.89
800
1000
1000
1000
1000
t~clJ
'I ' I  I. I . I 
. . . I '
Page 3 of 4
0U
· nrr
I ' '' I ' ' '. I .
,,4
IU'
0v
1- 3
:"'T'; "." : .
ZU.~r`
. . . I I ' I I I . . I . . I I I F I
9.27.07_BrdU_2uMDox.jo
101
100
800
600
~ 400
200
............................
n
I n 4
103
V)
-O
IL
102
10
0 200 400 600
FSC-H
Ungated
7.Dox.TNF_BrdU.PI_2uM_36
Event Count: 39907
10 3
102
101
100
200 400 600
FSC-H
Ungated
8.Dox.TNF BrdU.PI 2uM_48
Event Count: 41584
11/13/07 10:38 AM
800 1000 0 200 400 600
FL3-H: PI
singlets
7.Dox.TNF_BrdU.PI 
_2uM_36
Event Count: 29783
800
600
utvu
200
0
800 1000 0 200 400 600
FL3-H: PI
singlets
8.Dox.TNFBrdU.PI 
_2uM_48
Event Count: 30085
800 1000 0 200 400 600
FL3-H: PI
singlets
7.Dox.TNF BrdU.PI 2uM_36
Event Count: 29783
I 0
4
310
102
101
100
800 1000 0 200 400 600
FL3-H: PI
singlets
8.Dox.TNF BrdU.PI 2uM 48
Event Count: 30085
(FlowJo v6.4.7)
Layout-Batch
23.~."
A. ''
800 1000
800 1000
' ' ' I' ' I I - - II
I
-
I 111 I 1 ( l~lrll 1 I I I lllr 1 lrl I I IIllrl 1 I I (II Il
Page 4 of 4
0.01
-
7
Ant5
9.27.07_BrdU_ 10uM.jo
Layout-Batch
104
103
102
101
100
0 200 400 600
FSC-HUngated
1.BrdU.PI 10uM 2
Event Count: 35540
-. 4
103
d 102
10
10
100
0 200
Ungated
2.BrdU.PI 10uM_4
Event Count: 36062
400 600
FSC-H
2000
1500
O
S1000
500
0
800 1000 0 200 400 600
FL3-H: PI
singlets
1.BrdU.PI 10uM 2
Event Count: 30044
2000
1500
01000
500
..... . _ .. .. I.
800 1000 0 200 400 600
FL3-H: PI
singlets
2.BrdU.PI 10uM 4
Event Count: 30149
104
103
102
101
100
800 1000 0 200 400 600
FL3-H: PI
singlets
1.BrdU.PI_ 10uM_2
Event Count: 30044
800 1000
10 3
102
0 200 400 600
FL3-H: PI
singlets
2.BrdU.PI_10uM 4
Event Count: 30149
I Page 1 of 4
20.2
50.7
-.
0.41
26.4
4...
800 1000
800 1000
22.4
__......._.._.___ 
___
1 · r_
' ' ' I ' ' ' I ' ' ' I
I ' ' ' . ' I . I I I
(FlowJo v6.4.7)
11/13/07 10:52 AM
9.27.07_BrdU_10uM.jo
104
10
3
6102
U)
Ungated
3.BrdU.PI 10uM 8
Event Count: 38844
200 400 600
FSC-H
I " " 1 I
800 1000
1500
1000
500
0 200 400 600
FL3-H: PI
singlets
3.BrdU.PI_ 10uM_8
Event Count: 30466
104
103 -
102
101
100
800 1000
Layout-Batch
0 200 400 600
FL3-H: PI
singlets
3.BrdU.PI_10uM_8
Event Count: 30466
800 1000
104
103
10
2
101
100
0 200 400 600
FSC-H
Ungated
4.BrdU.PI 10uM 12
Event Count: 43307
1200
900
600
300
0
800 1000 0 200 400 600
FL3-H: PI
singlets
4.BrdU.PI 10uM_ 12
Event Count: 30907
104
10
10
1U
100
10
800 1000 0 2
singlets
4.BrdU.PI 10uM_12
Event Count: 30907
00 400 600 800 1000
FL3-H: PI
I Page 2 of 4
17.9
! ...................
"..::
..
F I I ' I . I . I . I I I . I . . I
---
(FlowJo v6.4.7)
11/13/07 10:52 AM
9.27.07_BrdU_ 10uM.jo
Layout-Batch
10
2
10 7
Ungated
7.BrdU.PI 10uM_36
Event Count: 46942
.......... I
200 400 600 800 1000
FSC-H
800
600
(n
S400
200
0 200 400 600
FL3-H: PI
singlets
7.BrdU.PI_10uM_36
Event Count: 30709
104
-3I
800 1000 0 200 400 600 800 1000
singlets
7.BrdU.PI 10uM 36
Event Count: 30709
104-
103-
3102
S)
101
10 °
I
0 200 400 600
FSC-H
Ungated
8.BrdU.PI 10uM_48
Event Count: 52345
800
600
400
200
.
'
800 1000 0 200 400 600
FL3-H: PI
singlets
8.BrdU.PI 10uM 48
Event Count: 30344
10v
3
10
--
101
.0O
Iv
800 1000 0 200 400 600
FL3-H: PI
singlets
8.BrdU.PI 10uM 48
Event Count: 30344
11/13/07 10:52 AM
.I 
' I ' ' ' I '
FL3-H: PI
800 1000
|
' 
_
.* .I I * I I , I * I I* I , , I
,,44
IIJ
I I
' ' .' 1 V ' I I ' ' I I I I I I . I I
Page 4 of 4 (FlowJo v6.4.7)
2.9 , 
.
42.3 . ..
7.22.5
Untitled Workspace.jo Layout-Batch
.- 4
103
10
1021
10
100
0 200
single cells
1.CycB.PI_UN 2
Event Count: 29862
400 600
FL3-H: Pl
104
103
S102
10 °
100
800 1000 0 200 400 600
FL3-H: PI
single cells
2.CycB.PI_UN_4
Event Count: 29918
800 1000 0 200 400 600
FL3-H: PI
single cells
3.CycB.PIUN 8
Event Count: 29909
104
103
C
a
102
10
101
100
0 200 400 600
FL3-H: PI
single cells
4.CycB.PI_UN_12
Event Count: 19902
0 200
single cells
5.CycB.PIUN 16
Event Count: 19855
400 600 800 1000
FL3-H: PI
0 200 400 600 800
FL3-H: PI
single cells
6.CycB.PI_UN_24
Event Count: 19965
104
10
3
m
102
i
LL_
10
10 0
1000 0 200 400 600
FL3-H: PI
single cells
7.CycB.PI UN 36
Event Count: 19798
.- 4
10"
103
102
101
100
800 1000
single cells
8.CycB.PI_UN 48
Event Count: 19819
200 400 600
FL3-H: PI
1/24/08 5:19 PM Page 1 of 1 (FlowJo v6.4.7)
800 1000
25.8
7.061 .
800 1000
1.631.63
' " 1 " ' I ' 1 I '
800 1000
· i: :·r:··.
r ..
5.:
i.·~: · ~.
"'
.v
-
Dox. i_PI.CycB_2pM_Dox.jo
Layout-Batch
1 u
10
3
m
-J 102
100
10 o0 0 200
single cells
1.CycB.Pl_2uM_2
Event Count: 19769
._1
400 600 800 1000 0 200 400 600FL3-H: PI FL3-H: PI
single cells
2.CycB.PI_2uM_4
Event Count: 19847
800 1000
4
0 200 400 600
FL3-H: PI
single cells
3.CycB.PI_2uM_8
Event Count: 19896
800 1000
104
10 3
m
( i02
.I_102
100
10°0
0 200 400 600
FL3-H: PI
single cells
4.CycB.PI_2uM_12
Event Count: 19837
10
10
3
S102
101
100
0 200
single cells
5.CycB.PI_2uM_16
Event Count: 19968
400 600
FL3-H: PI
10
4
10
3
S102
.0J
101
100
800 1000 0 200 400 600 800 1000 0 200 400 600
FL3-H: PI FL3-H: PIsingle cells
6.CycB.PI_2uM_24
Event Count: 20372
single cells
7.CycB.PI 2uM_36
Event Count: 20641
10
103
m
0102
-
1
LL
101
100
800 1000 0 200
single cells
8.CycB.PI_2uM_ 48
Event Count: 20490
400 600 800 1000
FL3-H: PI
1/24/08 5:30 PM Page 1 of 1 (FlowJo v6.4.7)
800 1000
104
103
0102
10
101
100
.4
cycB.PI.Doxl .jo Layout-Batch
10 4
10
3
L10 2
C,
101
100
i
I
200 400 600
FSC-H
400 600
FSC-H
Ungated
1.CycB.PI_10uM_ 2
Event Count: 21918
10 4
310
102
U/)
U)
10
100-
0 200
Ungated
2.CycB.PI_l10uM_ 4
Event Count: 21799
800 1000
800 1000
104
103
102
10
10 - 52.7
- . . r
0 200 400 600
FL3-H: PI
singlets
1.CycB.PI_10uM_ 2
Event Count: 19926
14.7
103
m
C
Ur
c.)
10110o
43.9 210 0 a
0 200
singlets
2.CycB.PI_10OuM_ 4
Event Count: 19960
400 600
FL3-H: PI
10
4
10 3
102
101
10
0ii.*.~1. I
0 200
Ungated
3.CycB.Pl_lOuM_ 8
Event Count: 22745
400 600
FSC-H
800 1000
104
103
m
10'
100
0 200 400 600
FL3-H: PI
singlets
3.CycB.P_I OuM_ 8
Event Count: 19701
4/29/08 1:39 PM
ji:7
30
_ '_"
. 9.7
-I-.
9.7
800 1000
' I
800 1000
34.5
6.89
i
800 1000
. . .
. .
. g s . . ,
.
r r
.·
"
'
''
5' -' '']'·'
,, ·~. . ·,
L
" I " " "
Page 1 of 3 (FlowJo v6.4.7)
cycB.PI.Doxl .jo Layout-Batch
*1I
S ,
200 400 600
FSC-H
800 1000
Ungated
4.CycB.PI_lOuM_ 12
Event Count: 24189
10
m
13
S-J
LL
101
10 -
0 200 400 600 800
FL3-H: PI
singlets
4.CycB.PI_10uM_ 12
Event Count: 19692
103
U)
U)
10
101
0 200 400 600
FSC-H
Ungated
5.CycB.PI_lOuM_l16
Event Count: 11850
104
10
3
I 0 2
o10
V)
10'
100 I I I
0 200 400 600
FSC-H
Ungated
6.CycB.PI_10uM_24
Event Count: 22759
800 1000
104
103
m
0102
.- J
LL
101
100
0 200 400 600 800 1000
FL3-H: PI
singlets
5.CycB.PI OuM_ 16
Event Count: 9776
800 1000
o103
J2
101
100 +39.
0
singlets
6.CycB.PI 10uM_24
Event Count: 19675
400 600 800 1000
FL3-H: PI
4/29/08 1:39 PM
20102
101
100
-
1000
.,.
S . I ' I
I 
I
31.2
18.1
,,4
49.6
I I I
- - I - I - i I
i
b
104
'l0 !
,v]
I I
Page 2 of 3 (FlowJo v6.4.7)
cycB.PI.Doxl .jo
IU103
0102
101
100
0 200 400 600
FSC-H
Ungated
7.CycB.PI_10OuM_36
Event Count: 11880
104
800 1000
I
m
(.E
jC
-J
,$
-I-
100
0
41.2
200 400 600 800 1000
FL3-H: PI
singlets
7.CycB.PI 10uM_36
Event Count: 9339
103
I102
10
100 I
0 200 400 600
FSC-H
Ungated
8.CycB.PI_10uM_48
Event Count: 24194
800 1000
I
10 o31
02
101
100-
0
31
22.4
200 400 600 800 1000
FL3-H: PI
singlets
8.CycB.PI 10uM_48
Event Count: 18637
4/29/08 1:39 PM
Layout-Batch
29.2
I I - . V
• 4
(FlowJo v6.4.7)
IV
i
10
i,
" 1 ' " 1 ' '
TI • 1 I
!
Page 3 of 3
1.12.08_Dox.3.pHH3.CycB. PI.jo Layout-1 -Batch
10
103
jf10
2
,U.
I
o100
0 200 400 600 800 1000
FL3-H: PI
singlets
1.pHH3.CycB.PI_UN_2
Event Count: 30043
4
singlets
2.pHH3
Event C
0 200 400 600 800 1000 0 200 400 600 800 1000
FL3-H: PI FL3-H: PI
singlets
.CycB.PI_UN_4 3.pHH3.CycB.PIUN_8
ount: 30039 Event Count: 30063
101 1
10-
102 j
01 .
mM11
0 200 400 600 800 1000
FL3-H: PI
singlets
4.pHH3.CycB.PI UN 12
Event Count: 30105
104
E10
2
10
o100
0 200 400 600 800 1000
FL3-H: PI
singlets
5.pHH3.CycB.PI_UN_16
Event Count: 29881
0 200 400 600 800 1000
FL3-H: PI
singlets
6.pHH3.CycB.PIUN_24
Event Count: 30039
._A
m
MCI
LL
0 200 400 600 800 1000
FL3-H: PI
singlets
7.pHH3.CycB.PI_UN_36
Event Count: 30031
10
3
102
101
100 
.
0 200 400 600 800 1000
FL3-H: PI
singlets
8.pHH3.CycB.PI UN 48
Event Count: 29964
0 200 400 600 800 1000
FL3-H: PI
singlets
9.pHH3.CycB.P 2pM_2
Event Count: 30034
10 -
10 -
10
2 -
101
0 200 400 600 800 1000
FL3-H: PI
singlets
10.pHH3.CycB.PL_2pM_4
Event Count: 30058
0 200 400 600 800 1000
FL3-H: PI
singlets
11 .pHH3.CycB.Pt_2pM_8
Event Count: 30046
0 200 400 600 800 1000
FL3-H: PI
singlets
12.pHH3.CycB.PI_2pM_12
Event Count: 30131
4/29/08 1:44 PM Page 1 of 2 (FlowJo v6.4.7)
i - - " I " " " | ' • • | • • •
100
iv
· '
· '
" " " 1 " " " " ' ' ' " I " 
•
I I ~I I I -- T
I I
I···I···I···I
1.12.08_Dox.3.pHH3.CycB. PI.jo Layout-i -Batch
10 
4
10 3,
U.
102
10
0 200 400 600 800 1000
FL3-H: PI
singlets
13.pHH3.CycB.Pl 2pM_16
Event Count: 30183
104-
10 -3
102
1
10'
loO-
0 200 400 600 800 100'
FL3-H: PI
singlets
17.pHH3.CycB.PI_10pM_2
Event Count: 29997
1U0
103
102
L.
101
100-
0 200 400 600 800 1000
FL3-H: PI
singlets
14.pHH3.CycB.PI_2pM_24
Event Count: 30245
10'
10 3 -
2-
#102.
10
. -0
0 0 200 400 600 800 1000
FL3-H: PI
singlets
18.pHH3.CycB.PI_10pM_4
Event Count: 30033
10' i
103 -
'102 .
10 -
singlets
15.pHH3.CycB.PI_2pM 36
Event Count: 29625
104
103
t102o
10
100.
0 200 400 600 800 1000
FL3-H: PI
singlets
19.pHH3.CycB.PI_10pM_8
Event Count: 30068
10 3-
t 10
2
10
• ^o
0 200 400 600 800 1000
FL3-H: PI
singlets
16.pHH3.CycB.PI _2pM_48
Event Count: 29367
104
10 3
Cl
:j
U_102
10
10 
0 200 400 600 800 1000
FL3-H: PI
singlets
20.pHH3.CycB.Pl_10pM_12
Event Count: 30091
0 200 400 600 800 1000
FL3-H: PI
singlets
21.pHH3.CycB.PI_10pM_16
Event Count: 30137
104
2:
10 3
10
10o2
1
101
-o
0 200 400 600 800 1000
FL3-H: PI
singlets
22.pHH3.CycB.PI_10pM_24
Event Count: 29533
4/29/08 1:44 PM
103
±10
2
101
-
010
2:
u.
0 200 400 600 800 -1000
FL3-H: PI
singlets
23.pHH3.CycB.PI_10pM_36
Event Count: 23763
Page 2 of 2
103
102
10
100
0 200 400 600 800 1000
FL3-H: PI
singlets
24.pHH3.CycB.P_ 10pM_48
Event Count: 16599
4.21e-3
(FlowJo v6.4.7)
10 " " " I " " " I " " • I " ' " I ' " '
4
.^4
100I
0 200 400 600 800 1000
FL3-H: PI
, , , 
, ,
·C~·:·i~:.;:
~i·?1-·· · ·
·''
1·;·~r· r.
I I 
I I 
I
in-
I
1UW_ - I · I · I · I 1 I • ' I ' ' I ' " I " ' I ' " I
.- A
III100- - • • i • • • • • i • • • I • I 1 . . . . . . . , = s . g . . r g
It#
•4
,Go • • i - •- - -• i • • I ! ' I I' '
